Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.54 |
| ▸ | ACKR3 | P25106 | 6/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | PPP5C | P53041 | 2/20 | 0.36 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15554584 | 0.83 | PPP5C (0.53) | ACKR3KCNH2PPP5CPPP2CA | |
| SCHEMBL12390225 | 0.72 | TFPI2 (0.50) | HSD11B1KMT2APPP5CPPP2CA | |
| SCHEMBL9880154 | 0.72 | TFPI2 (0.70) | HSD11B1PPP5CPPP2CA | |
| SCHEMBL16731305 | 0.72 | TFPI2 (0.70) | HSD11B1PPP5CPPP2CA | |
| SCHEMBL14595386 | 0.71 | HSD11B1 (0.58) | HSD11B1KMT2AHRH3 | |
| SCHEMBL20937145 | 0.71 | HSD11B1 (0.43) | HSD11B1ACKR3KCNH2 | |
| SCHEMBL7903517 | 0.70 | HSD11B1 (0.82) | HSD11B1KMT2A | |
| SCHEMBL14595387 | 0.69 | HSD11B1 (0.63) | HSD11B1 | |
| SCHEMBL14424154 | 0.68 | MEN1 (0.39) | KCNH2KMT2A | |
| SCHEMBL8247132 | 0.68 | MEN1 (0.39) | KCNH2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399993-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2018-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399993-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | HSD11B1 56/4885ACKR3 1303/4885KCNH2 3159/4885 |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | HSD11B1 56/4885ACKR3 1303/4885KCNH2 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.